Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SPR | P35270 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24037263 | 0.84 | TSHR (0.40) | LMNATSHRGLAUSP2MEN1 | |
| SCHEMBL24037435 | 0.83 | USP2 (0.54) | LMNATSHRGLAUSP2MEN1 | |
| SCHEMBL24037486 | 0.81 | LMNA (0.38) | LMNATSHRSPRGLAUSP2 | |
| SCHEMBL24037531 | 0.79 | HTR2C (0.42) | LMNATSHRMEN1KMT2AKDM4E | |
| SCHEMBL24037529 | 0.79 | HTR2C (0.42) | LMNATSHRMEN1KMT2AKDM4E | |
| SCHEMBL30776995 | 0.77 | LMNA (0.41) | LMNATSHRSPRGLAUSP2 | |
| SCHEMBL30777001 | 0.77 | LMNA (0.41) | LMNATSHRSPRGLAUSP2 | |
| SCHEMBL24037650 | 0.77 | LMNA (0.41) | LMNATSHRSPRGLAUSP2 | |
| SCHEMBL24037264 | 0.76 | KDM4E (0.50) | LMNATSHRMEN1KMT2AKDM4E | |
| SCHEMBL24037407 | 0.74 | LMNA (0.33) | LMNATSHRUSP2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210355124-A1 | Cyclic compounds as receptor modulating therapeutics and methods and uses thereof | BIONOMICS LIMITED (AU) | 2021-11-18 | — | — | US | disclosed |
| WO-2020077414-A1 | CYCLIC COMPOUNDS AS RECEPTOR MODULATING THERAPEUTICS AND METHODS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355124-A1 | Cyclic compounds as receptor modulating therapeutics and methods and uses thereof | CHRNA7, CHRNA1, CHRNA5 | LMNA 2733/4885TSHR 258/4885SPR 1663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.